Precision medicine has emerged as a transformative approach to healthcare, enabling tailored treatments based on individual genetic, environmental, and lifestyle factors. However, the high costs and complexities associated with biomarker discovery, companion diagnostics, and personalized therapeutic development present significant financing challenges. This review evaluates current investment models supporting precision medicine, including public funding, venture capital, industry partnerships, and philanthropic contributions. It examines recent investment trends, geographic distribution of funding, and focus areas such as oncology and rare diseases. Key challenges identified include regulatory uncertainties, long development timelines, and market access barriers. The review also explores innovative financing strategies, such as outcome based contracting and integration of digital technologies, which hold promise for de risking investments and accelerating therapeutic innovation. The findings underscore the critical need for collaborative, flexible, and adaptive financial frameworks to sustain the growth of precision medicine and ensure equitable patient access. This paper provides strategic insights for stakeholders aiming to optimize investment approaches that can unlock the full potential of personalized healthcare.